Jaksch Frank L Jr 4

What Happened

• Frank L. Jaksch Jr., a director of Niagen Bioscience, was granted a derivative award on 2026-06-24 covering 31,746 shares. The Form 4 reports an acquisition amount of $0 (this reflects an option/award grant, not a cash purchase or sale).

Key Details

• Transaction date: 2026-06-24; filing date: 2026-06-26 (filed two days after the transaction).
• Reported price/amount: $0 (derivative award, not an open-market purchase).
• Shares awarded: 31,746 (option/award form); reported as a derivative grant on the Form 4.
• Vesting: Option vests 100% on 2027-06-24 (Footnote F1).
• Shares owned after transaction: not specified in the summary provided (see the full Form 4 for total beneficial ownership).
• No indication of a 10b5-1 plan, sale, tax withholding, or late filing in this summary.

Context

• This was an awarded option grant (compensation), not an immediate purchase or sale. The $0 shown on the Form 4 reflects the grant reporting; the economic value of the award (fair value) is typically disclosed in proxy statements or Form 8-K/compensation filings.
• Award grants are common for directors and reflect compensation or retention, and do not by themselves indicate buying or selling sentiment.